Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

President Trump and Health HHS Secretary Robert F. Kennedy Jr. want to Make America Healthy Again. It's going to take more ...

Rapid weight loss without adequate nutrition can lead to a reduction in lean muscle mass, and many patients experience ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Estrogen generated in the brain may play a role in regulating appetite, potentially opening new avenues for treating obesity.

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...